A study by You and colleagues analysed the rates and clinical outcomes of combined alterations of pTERT mutations and other key markers including IDH1/2, EGFR, TP53, PTEN, MGMT and 1p19q, in gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.